

PROGRAMME

DZIF Annual Meeting

German Center for Infection Research (DZIF)

3 – 4 December 2018

Kongresshaus Stadthalle Heidelberg

Conference Chairs:

Prof. Dr. K. Heeg

Prof. Dr. H.-G. Kräusslich

PD Dr. Dr. A. Riemer

Prof. Dr. S. Urban

www.dzif-annual-meeting2018.de

Greeting p. 3

Scientific Programme – Programme at a Glance p. 4

 Monday, 3 December 2018 p. 6

 Tuesday, 4 December 2018..... p. 9

Poster Sessions / Awards..... p. 12

DZIF TI-Forum / DZIF-Academy fellows..... p. 13

Poster..... p. 14

Speakers, Chairs & Presenting Authors p. 30

General Information p. 33

Registration p. 34

Sponsors & Exhibitors..... p. 35

Travel Information..... p. 36

Imprint p. 39


Conference Chairs

Prof. Dr. Klaus Heeg | University Hospital Heidelberg
 Prof. Dr. Hans-Georg Kräusslich | University Hospital Heidelberg
 PD Dr. Dr. Angelika Riemer | German Cancer Research Center Heidelberg
 Prof. Dr. Stephan Urban | University Hospital Heidelberg

Organizing Committee

Dr. Timo Jäger
 Simone Friedrich
 Tatiana Hilger

DZIF e.V., Braunschweig
 Contact: office@dzif.de



Dear colleagues,

We cordially invite you to this year's Annual Meeting of the German Center for Infection Research (DZIF) in Heidelberg.

Virtually every day, we see just how much infection medicine is gaining in importance, not only owing to breakouts of seasonal illnesses. We are also seeing a growing significance of multi-resistant bacteria. Furthermore, we are facing germs from various regions around the world entering Germany due to high levels of travel and migration.

The German Center for Infection Research is specialised in translational research that utilises insights from basic biomedical research into clinical application. For this reason, we have defined various overarching topics for the conference in Heidelberg, which the DZIF research fields and infrastructures (TTUs and TIs) can and shall present. In addition, we would like to call attention to interaction and overlapping with other German Centers for Health Research. This is why we have planned a symposium in collaboration with the German Center for Lung Research (DZL) to address common aspects of lung infection research.

It will feature presentations, a poster exhibition and additional opportunities to share experiences. The setting in and surrounding the Heidelberg Stadthalle is also conducive to good and intensive communication. We believe this conference will provide the opportunity to further strengthen networking inside the DZIF and with other health research centers.

We are looking forward to welcoming you in Heidelberg from 3 to 4 December 2018.

Best regards,

Your Conference Chairs



Prof. Dr. Klaus Heeg



Prof. Dr. Hans-Georg Kräusslich



PD Dr. Dr. Angelika Riemer




Prof. Dr. Stephan Urban

MONDAY, 3 DECEMBER 2018

11:00 – 11:10	Welcome	
11:10 – 12:40	Symposium I: Resistance Mechanisms	p.6
12:40 – 13:40	Lunch Break and Industrial Exhibition	13:00 – 14:00 MSD Lunch Symposium “Immunsystem am Limit” p.7
13:40 – 14:40	Poster Session I	
14:40 – 16:10	Symposium II: Novel Anti-Infectives	p.8
16:10 – 16:40	Coffee Break and Industrial Exhibition	
16:40 – 18:10	Symposium III: Immunotherapy/Vaccines	p.8
18:10	Poster viewing & Get together with food and drinks p.8	Meeting of the DZIF- Academy fellows p.8


TUESDAY, 4 DECEMBER 2018

09:00 – 10:30	Symposium IV: Infections of the Lung	p.9
10:30 – 11:00	Coffee Break and Industrial Exhibition	
11:00 – 12:00	Poster Session II	p.9
12:00 – 13:00	Reports from DZIF-funded clinical studies	p.9
13:00 – 14:00	Lunch Break and Industrial Exhibition	
14:00 – 14:10	DZIF Poster Awards	p.10
14:10 – 14:40	DZIF Award Lecture	p.10
14:40 – 14:50	Group Photo	p.10
14:50 – 15:20	Coffee Break and Industrial Exhibition	
15:20 – 16:50	Symposium V: Global Intervention Effectiveness	p.10
16:50 – 17:00	Closing Remarks p.11	




ST = Short Talk, AT = Academy Talk

11:00 – 11:10 Main Hall	Welcome <i>M. Krönke, Cologne</i> <i>K. Heeg, Heidelberg</i>
11:10 – 12:40 Main Hall	Symposium I: Resistance Mechanisms <i>Chairs: A. Peschel, Tübingen</i> <i>S. Portugal, Heidelberg</i>
11:10 – 11:40 Keynote-Lecture	Investigating the drivers of antibiotic resistance and success in Methicillin-resistant <i>Staphylococcus aureus</i> <i>M. Holden, St. Andrews (UK)</i>
11:40 – 11:55 ST 1	Humanized mice recapitulate species-specific Ebola virus pathogenesis <i>B. Escudero Perez¹, P. Ruibal¹, M. Rottstegge¹, A. Lüdtke¹, K. Hartmann¹, S. Gómez Medina¹, J. Müller-Guhl¹, E. V. Nelson¹, S. Krasemann¹, E. Mühlberger², E. Rodriguez¹, C. Muñoz Fontela¹, ¹Hamburg, ²Boston (USA)</i>
11:55 – 12:10 ST 2	Retrospective analysis of <i>Enterobacter</i> species reveals the cosmopolitan existence of highly pathogenic <i>E. bugandensis</i> <i>S. Dojjad, C. Imirzalioglu, T. Chakraborty, Gießen</i>
12:10 – 12:25 ST 3	Persistence of HCV resistance-associated substitutions after treatment failure and implications for treatment <i>J. Dietz¹, J. Vermehren¹, T. M. Welzel¹, J. Petersen², K. Matschenz², C. Antoni³, B. Müllhaupt⁴, S. Mauss⁵, C. Niederau⁶, T. von Hahn⁷, J. Schulze zur Wiesch², C. Neumann-Haefelin⁸, C. Berg⁹, T. Berg¹⁰, S. Zeuzem¹, C. Sarrazin^{1,11}</i> ¹ Frankfurt am Main, ² Hamburg, ³ Mannheim, ⁴ Zürich (Switzerland), ⁵ Düsseldorf, ⁶ Oberhausen, ⁷ Hanover, ⁸ Freiburg, ⁹ Tübingen, ¹⁰ Leipzig, ¹¹ Wiesbaden
12:25 – 12:40 ST 4	<i>MecB</i> mediates beta-lactam resistance in different <i>Staphylococcus aureus</i> strain backgrounds <i>S. van Alen, U. Kaspar, N. Schleimer, E. Idelevich, G. Peters, K. Becker, Münster</i>
12:40 – 13:40	Lunch Break and Industrial Exhibition



13:00 – 14:00	MSD Symposium „Immunsystem am Limit“: Der Patient zwischen Viren & Bakterien <i>Vorsitz: R. Kaiser, Köln</i>
13:00 – 13:40	CMV – Diagnostik & Management: Wo sind die Fallstricke und was gibt es Neues? <i>R. Kaiser, J.-J. Vehreschild, Köln</i>
13:40 – 14:00	Clostridium Difficile Infektionen: Zwischen Mikrobiom und passiver Immunisierung? <i>O. Bachmann, Hannover</i>
The Symposium is organized by MSD SHARP & DOHME GmbH, Munich.	
13:40 – 14:40 (1 st level)	Poster Session I For further information please see page 12
14:40 – 16:10 Main Hall	Symposium II: Novel Anti-Infectives <i>Chairs: C. Meier, Hamburg</i> <i>T. Schneider, Bonn</i>
14:40 – 15:10 Keynote-Lecture	Bacterial lectins as targets for diagnostics and antiinfectives <i>A. Titz, Saarbrücken</i>
15:10 – 15:25 ST 5	Modification of vancomycin leads to conjugates that overcome all types of resistance <i>F. Umstätter¹, C. Domhan¹, P. Uhl¹, B. Beijer¹, C. Kleist¹, K. Leotta¹, S. Zimmermann¹, M. Wink¹, K. D. Klika¹, U. Haberkorn¹, T. Hertlein², K. Ohlsen², <u>W. Mier¹</u>, ¹Heidelberg, ²Würzburg</i>
15:25 – 15:40 ST 6	Alpha-Ketomides as potential inhibitors of HCoV-229E and HCoV-NL63 replication <i>D. R. Bairad¹, S. Schwinghammer¹, Y. Ma-Lauer¹, B. von Brunn¹, R. Hilgenfeld², A. von Brunn¹, ¹Munich, ²Lübeck</i>
15:40 – 15:55 ST 7	Biosynthesis and engineering of hydroxamic acid-containing antibacterial inhibitors of the peptide deformylase <i>F. Leipoldt¹, F. Wolf¹, J. Santos-Aberturas², A. Kulik¹, D. Wibberg³, J. Kalinowski³, H. Gross¹, A. Truman², <u>L. Kaysser¹</u>, ¹Tübingen, ²Norwich (UK), ³Bielefeld</i>
15:55 – 16:10 AT 1	Am80 (tamibarotene), an agonist of the retinoic acid receptor α, specifically inhibits hepatitis B viral transcription <i>S. Nkongolo, F. A. Lempp, L. Nußbaum, B. Qu, S. Urban, Y. Ni, Heidelberg</i>

16:10 – 16:40	Coffee Break and Industrial Exhibition
16:40 – 18:10 Main Hall	Symposium III: Immunotherapy/Vaccines <i>Chairs: S. Becker, Marburg</i> <i>L. Cicin-Sain, Braunschweig</i>
16:40 – 17:10 Keynote-Lecture	Epstein-Barr virus – a human tumor virus on its way to a vaccine candidate <i>W. Hammerschmidt, Munich</i>
17:10 – 17:25 ST 8	MAVACHE: a dose and schedule optimization trial of intravenous immunization against malaria with PfSPZ vaccine <i>B. Mordmüller^{1,2}, Z. Sulyok¹, A. Lalremruata¹, J. Weirich¹, Z. Molnár¹, A. Theurer¹, C. Lamsfus Calle¹, M. Esen¹, M. Sulyok¹, T. L. Richie³, B. K. L. Sim³, S. L. Hoffman³, P. G. Kreamsner^{1,2}, ¹Tübingen, ²Lambaréné (Gabon), ³Rockville (USA)</i>
17:25 – 17:40 ST 9	The measles virus-based vaccine platform is highly immunogenic against emerging pathogens and induces long-lasting immunity <i>C. Nürnberger¹, A. H. Fiedler¹, B. S. Bodmer¹, S. Prüfer¹, A. Kupke², V. A. Scheuplein¹, L. Walz¹, G. Gabriel³, V. von Messling¹, S. Herold⁴, S. Becker², M. D. Mühlebach¹, ¹Langen, ²Marburg, ³Hamburg, ⁴Gießen</i>
17:40 – 17:55 ST 10	Neutrophils as targets for host-directed therapy against tuberculosis <i>T. Dallenga¹, U. Repnik², L. Linnemann¹, H. Tijani¹, C. Leszczczyk¹, R. Reimer^{1,3}, G. Griffiths², U. E. Schaible¹, ¹Borstel, ²Oslo (Norway), ³Hamburg</i>
17:55 – 18:10 AT 2	The clinical phase 1 MVA-MERS-S vaccine trial shows the vaccine to be safe, well-tolerated and eliciting immune responses <i>A. Fathi^{1,2}, T. Koch^{1,2}, C. Dahlke^{1,2}, V. Krähling^{3,4}, A. Kupke^{3,4}, S. Halwe^{3,4}, C. Rohde^{3,4}, M. Eickmann^{3,4}, A. Volz⁵, T. Hestekamp⁶, A. Jambrecina¹, L. Kaltenberg¹, S. Borregard¹, M. L. Ly^{1,2}, M. Zinser^{1,2}, E. Bartels^{1,2}, J. Poetsch^{1,2}, R. Neumann^{1,2}, R. Fux⁵, S. Schmiedel¹, F. Stahl^{1,2}, A. Lohse¹, G. Sutter⁶, S. Becker^{3,4}, M. Addo^{1,2}, ¹Hamburg, ²Hamburg-Lübeck-Borstel-Riems, ³Marburg, ⁴Gießen-Marburg-Langen, ⁵Munich, ⁶Braunschweig</i>
18:10	Poster viewing & Get together with food and drinks
from 18:10 Kammermusiksaal (1 st level)	Meeting of the DZIF-Academy fellows For further information please see page 13



9:00 – 10:30 Main Hall	Symposium IV: Infections of the Lung <i>Chairs: A. Dalpke, Heidelberg</i> <i>S. Herold, Marburg</i>
9:00 – 9:30 Keynote-Lecture	Influenza 2018 – What caused such a high burden of disease? <i>T. Welte, Hanover</i>
9:30 – 9:45 ST 11	Genetic determinants of severe respiratory syncytial virus infections in infants <i>S. Haid¹, M. Wetzke¹, C. Lauber², D. Todt³, L. Kaderali⁴, R. Geffers⁵, E. Vafadarnejad⁶, B. Wiegmann¹, E. Steinmann³, E. Saliba⁶, T. F. Schulz¹, G. Hansen¹, T. Pietschmann¹ ¹Hanover, ²Dresden, ³Bochum, ⁴Greifswald, ⁵Braunschweig, ⁶Würzburg</i>
9:45 – 10:00 ST 12	Outcome predicting transcriptional signature in patients with M/XDR-TB <i>J. Heyckendorff^{1,2}, M. Reimann^{1,2}, B. Kalsdorf^{1,2}, P. Sanchez-Carballo^{1,2}, T. Goldmann¹, C. Lange^{1,2}, S. Marwitz¹, ¹Borstel, ²Hamburg-Lübeck-Borstel</i>
10:00 – 10:15 ST 13	Mycobacterium tuberculosis exploits WNT6-induced perturbation of host lipid homeostasis to facilitate growth in macrophages <i>J. Brandenburg¹, S. Marwitz¹, B. Karlsdorf¹, T. Scholzen¹, A. Gross¹, S. Goldenbaum¹, M. Hein¹, A. Kispert², M. Leitges³, J. Rupp⁴, C. Lange^{1,4}, S. Niemann^{1,4}, C. Hölscher¹, J. Behrends¹, T. Goldmann^{1,4}, U. E. Schaible^{1,4}, D. Schwudke¹, N. Reiling¹, ¹Borstel, ²Hanover, ³Oslo (Norway), ⁴Lübeck</i>
10:15 – 10:30 AT 3	Defining a signature for distinct disease states in pulmonary tuberculosis using RNA sequencing <i>M. Ahmed, L. Rogers, J. Buschbeck, M. Rohlf, M. Hoelscher, N. Heinrich, C. Geldmacher, U. von Both, Munich</i>
10:30 – 11:00	Coffee Break and Industrial Exhibition
11:00 – 12:00 1 st level	Poster Session II For further information please see page 12
12:00 – 13:00 Main Hall	Reports from DZIF-funded clinical studies <i>Chairs: M. Addo, Hamburg</i> <i>O. Cornely, Cologne</i>
12:00 – 12:15	Interim results of a Phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFN alpha 2a in CHB/CHD patients <i>S. Urban, Heidelberg</i>

ST = Short Talk, AT = Academy Talk

12:15 – 12:30 **BTZ-043 – Pre-clinical and clinical development of a new drug against tuberculosis**
M. Hölscher, Munich

12:30 – 12:45 **Update on the IMMUC study**
U. Behrends, Munich

12:45 – 13:00 **Pneumococcal vaccination of hemodialysis patients – A prospective non-interventional multicenter study analyzing the duration of protection**
S. Mellinghoff, Cologne

13:00 – 14:00 **Lunch Break and Industrial Exhibition**

14:00 – 14:10 **DZIF Poster Awards**
Main Hall

14:10 – 14:40 **DZIF Award Lecture**
Main Hall
Chair: U. Protzer, Munich

14:40 – 14:50 **Group Photo**

14:50 – 15:20 **Coffee Break and Industrial Exhibition**

15:20 – 16:50 **Symposium V: Global Intervention Effectiveness**
Main Hall
*Chairs: M. Hölscher, Munich
J. May, Hamburg*

15:20 – 15:50 **Innovations in Population Health and Intervention Research**
Keynote-Lecture
T. Bärnighausen, Heidelberg

15:50 – 16:05 **Crossectional study reveals promising biomarker to distinguish Malaria tropica from bacterial bloodstream infections**
ST 14
*N. Gilberger¹, M. Zimmermann¹, D. Eibach¹, R. Krumkamp¹, E. Lorenz¹, N. Sarpong^{1,2}, Team Agogo², Team KCCR³, E. Owusu-Dabo³, J. May¹,
¹Hamburg, ²Agogo (Ghana), ³Kumasi (Ghana)*

16:05 – 16:20 **The HIV2EU project: current strategies and tools for the care of HIV-2 infective/positive individuals living in Europe**
ST 15


*D. Berzow^{1,2}, S. Matheron³, R. Kaiser^{1,2,4,5,6,7}, M. Obermeier⁸, L. Gürtler⁸, J. Eberle^{1,8}, D. Descamps³, C. Charpentier³, M. Dring⁹, J. Ruelle¹⁰, N. Taylor¹¹, S. Sierra^{4,7}, M. Stürmer¹², B. Jensen^{1,13}, J. Rockstroh^{1,14}, R. Camacho¹⁵
¹Hamburg, ²Berlin, ³Paris (France), ⁴Cologne, ⁵Rheinbach, ⁶Freiburg, ⁷Cologne, ⁸Munich, ⁹Saarbrücken, ¹⁰Brussels (Belgium), ¹¹Salzburg (Austria), ¹²Frankfurt, ¹³Düsseldorf, ¹⁴Bonn, ¹⁵Leuven (Belgium)*

16:20 – 16:35 **The silent reservoir of P. falciparum during the dry season**
ST 16
*C. Andrade¹, H. Fleckenstein¹, S. Doumbo², A. Ongoiba², K. Kayentao², O. Doumbo², B. Traore², P. Crompton³, S. Portugal¹, Heidelberg,
²Bamako (Mali), ³Rockville (USA)*

16:35 – 16:50 **Impact of single room contact precautions on hospital-acquisition and transmission of vancomycin-resistant enterococci in a high-risk setting – preliminary results from the CONTROL study**
AT 4
*L. M. Bieh¹, P. G. Higgins¹, J. Stemler¹, M. Gillis¹, S. Peter², D. Dörfel², W. Vogel², W. V. Kern³, H. Gölz³, H. Bertz³, H. Rohde^{4,11}, E.-M. Klupp⁴, P. Schafhausen⁴, J. Salmanton-García¹, J. Ertel¹, J. Zweigner¹, H. Seifert¹, M. J. Vehreschild¹,
¹Cologne, ²Tübingen, ³Freiburg, ⁴Hamburg*

16:50 – 17:00 **Closing Remarks**
Main Hall





Poster Sessions

The poster exhibition will take place on the 1st floor.

Posters shall be prepared in DIN A0 size (1189mm x 841mm), portrait format, in English language. The dimensions of the poster walls are 2m (height) x 0,95m (width), material to fix the posters will be provided.

All posters should be mounted on Monday, 3 December 2018 from 9:00 – 11:00. Please remove your poster after the congress on Tuesday, 4 December 2018, from 17:00 – 18:00. It is not possible to send remaining posters back to you after the congress. Please note that remaining posters have to be disposed of.

All authors are kindly asked to be present at their posters during the poster sessions on Monday, 3 December 2018, from 13:40 – 14:40 and on Tuesday, 4 December 2018, from 11:00 – 12:00 for questions and discussion.

Poster Awards

The three best posters will be awarded with EUR 500,- each. The presentation of awards will take place on Tuesday, 4 December 2018, from 14:00 - 14:10.

Our sincere thanks go to MSD SHARP & DOHME GMBH for its support.

DZIF-Prize for Translational Research

The DZIF will award the 5th DZIF Prize for Translational Infection Research endowed with EUR 5.000,-.

The prize will be awarded on Tuesday, 4 December from 14:10-14:40, where the recipient will have the chance to present his or her research.

Abstract Book

The Abstract Book will be available online at the conference website. You will also receive a USB flash drive with the Abstract book.

DZIF TI-Forum

At the same time of the poster sessions, representatives of following DZIF Translational Infrastructures (TI) will present their services:

- Product Development Unit
- Clinical Trial Unit
- African Partner Institutions
- Biobanking
- Epidemiology
- Bioinformatics
- Pathogen Repository
- Novel Antivirals

Take advantage of the opportunity to find out how the TIs can support your research.

The DZIF Academy will also present its programmes. The aim of the DZIF Academy is to educate and train the next generation of researchers in infectious diseases. Highly attractive educational programmes for students and postgraduates are fundamental for excellent basic, translational and clinician scientists.

Further, the DZIF Transplant Cohort e.V. – a large multicenter prospective observational cohort of transplant recipients and donors – will give an overview of its work.

The Global Antimicrobial Resistance Research and Development Hub (Global AMR R&D Hub) – the initiative of G20, launched this year – will also present itself.

Meeting of the DZIF-Academy fellows

Monday, 3 December 2018, from 18:10, Kammermusiksaal

Get to know other DZIF-Academy fellows and learn more about opportunities, news and events of the DZIF-Academy:

The meeting offers young scientists the possibility to expand their network and to exchange information with other fellows. Take advantage of the opportunity to learn from and with each other. There will be ample scope for discussing and developing ideas concerning present and future Academy activities.

SY I: RESISTANCE MECHANISMS

P 1

Evaluation of candidate species in reducing gastrointestinal *Pseudomonas aeruginosa* colonization
 F. Hölzl, H. Hinkov, M. Willmann, M. El-Hadidi, A. Lange, S. Peter, K. Gronbach, I. Autenrieth, J.-S. Frick, Tuebingen

P 2

Microbiota-associated risk factors for *C. difficile* acquisition in hospitalized patients:

A prospective, multicentric study

P. Solbach^{1,2}, P. Chhatwal^{1,2}, S. Woltemate^{1,2}, E. Tacconelli³, M. Buhl³, M. J. Vehreschild^{4,5}, N. Jazmati^{4,5}, M. Gerhard⁶, C. K. Thoeringer⁶, J. Rupp^{7,8}, K. Ulm⁶, A. Koch¹, M. P. Manns^{1,2}, S. Suerbaum^{1,2,6}, O. Bachmann^{1,2}, ¹Hanover, ²Braunschweig, ³Tuebingen, ⁴Cologne, ⁵Bonn, ⁶Munich, ⁷Lübeck, ⁸Hamburg-Borstel-Lübeck

P 3

Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* clinical isolates between 2012 and 2016 – results from a worldwide surveillance study

C. Müller¹, D. Stefanik¹, J. Ertel¹, M. Hacke², P. G. Higgins¹, H. Seifert¹, ¹Cologne, ²Schaumburg (USA)

P 4

Hepatitis B virus (HBV) DNA integration is not driven by viral proteins

T. Tu¹, B. Zehnder¹, M. Levy², G. Micali², L. Tran², O. Dabere², N. Main², N. Shackel², S. Urban¹, ¹Heidelberg, ²Sydney (Australia)

P 5

Clinically relevant Gram-negative isolates present in recreational and surface water

L. Falgenhauer¹, C. Gerstmann¹, C. Baars², O. Lambrecht², T. Chakraborty¹, C. Imirzalioglu¹, ¹Giessen, ²Hamburg

P 6

***E. coli* ST206 encoding the emerging ESBL gene *bla*_{CTX-M-27} detected in Nigerian poultry farms**

J. Falgenhauer¹, F. A. Ayeni², S. Olofinsae², J. Schmiedel¹, C. Imirzalioglu¹, T. Chakraborty¹, L. Falgenhauer¹, ¹Giessen, ²Ibadan (Nigeria)

P 7

Pre Treatment HIV-1 Drug Resistance in Transmission Clusters of the Cologne-Bonn Region, Germany

M. Stecher¹, A. Chaillon², A. M. Eis-Hübinger³, C. Lehmann¹, G. Fätkenheuer¹, J.-C. Wasmuth³, E. Knops¹, J.-J. Vehreschild¹, S. Mehta², M. Hoenig^{2,4}, ¹Cologne, ²San Diego (USA), ³Bonn, ⁴Graz (Austria)

P 8

Bloodstream Infection due to Multidrug-Resistant Organisms – Multicenter Study on Determinants of Clinical Outcomes (BLOOMY.COM): First 18-month study results

S. Eisenbeis¹, M. Buhl¹, B. P. Gladstone¹, C. Cattaneo², A. M. Rohde³, J. C. Falgenhauer⁴, N. Kaeding^{5,6}, A. Mischik^{5,6}, M. Vehreschild^{7,8}, P. Gastmeier³, T. Chakraborty⁴, H. Seifert^{7,8}, J. Rupp^{5,9}, W. Kern^{2,9}, E. Tacconelli^{1,10}, F. Hölzl^{1,3}, ¹Tuebingen, ²Freiburg, ³Berlin, ⁴Gießen, ⁵Lübeck, ⁶Hamburg-Lübeck-Borstel, ⁷Cologne, ⁸Bonn, ⁹Braunschweig, ¹⁰Verona (Italy)

P 9

Molecular insights into mechanism leading to MCR-1-induced colistin resistance

K. Gwozdziński, M. Hudel, S. Azarderakhsh, C. Imirzalioglu, T. Chakraborty, L. Falgenhauer, Gießen

P 10

Genetic background of carbapenem non-susceptibility in *Acinetobacter pittii* isolates mediated by metallo-β-lactamases

A. Wunderlich, K. Xanthopoulou, J. Ertel, S. Gerson, H. Seifert, P. Higgins, Cologne

P 11

Epistatic interactions in NS5A of Hepatitis C virus suggest drug resistance mechanisms

S. Sierra¹, E. Knops¹, P. Kalaghatgi², E. Heger¹, R. Kaiser¹, O. Kalinina², ¹Cologne, ²Saarbrücken

P 12

The Clinical Research Unit (CRU): Focusing on the clinical and epidemiological aspects of healthcare-associated infections in 2017/18

S. Eisenbeis¹, A. Savoldi¹, S. Döbele¹, F. Foschi¹, B. P. Gladstone¹, E. Tacconelli^{1,2}, ¹Tuebingen, ²Verona (Italy)

P 13

Preliminary NGS data analysis of Coronavirus NL63 and 229E genomes under high pressure selection conditions with cyclophilin inhibitors

S. Schwinghammer, D. R. Bairad, Y. Ma-Lauer, B. von Brunn, H. Blum, A. von Brunn, Munich

P 14

Dual role of antigen-presenting cells during Ebola virus infection

E. Nelson¹, N. Hertoghs², A. Ludtke¹, S. Gunther¹, S. Krasemann¹, J. Idoyaga³, L. Oestereich¹, T. Geijtenbeek², E. Dietzel⁴, S. Becker⁴, C. Muñoz-Fontela¹, ¹Hamburg, ²Amsterdam (Netherlands), ³Stanford (USA), ⁴Marburg

P 15

Impact of antibiotics on the gut resistome: A prospective clinical metagenomics multicenter cohort study

M. Willmann¹, M. J. Vehreschild², L. M. Bieh², W. Vogel¹, D. Dörfel¹, A. Hamprecht², H. Seifert², I. Autenrieth¹, S. Peter¹, ¹Tuebingen, ²Cologne

P 16

The microbiome of the bladder in healthy women. A longitudinal pilot study (MiHoP)

L. M. Bieh¹, A. Tsakmaklis¹, F. Farowski¹, C. Hilpert¹, A. Nowag¹, H. Wisplinghoff^{1,2}, M. J. Vehreschild¹, ¹Cologne, ²Witten

P 17

Genome-based epidemiology of KPC3-Carbapenemase producing *Klebsiella pneumoniae* in Hessen
 Y. Yao¹, A. Hauri², L. Falgenhauer¹, V. A. Kempf³, R. Schmithausen⁴, M. Exner⁴, U. Heudorf³,
 P. Heinmüller², J. Falgenhauer¹, O. Schwengers¹, M. Fritzenwanker¹, E. Domann¹, T. Chakraborty¹,
 C. Imirzalioglu¹, ¹Giessen, ²Dillenburg, ³Frankfurt am Main, ⁴Bonn

P 18

Resolving the genetic structure of mobile genetic elements associated with the carbapenemase bla_{OXA-235-like} in *Acinetobacter baumannii*
 K. Xanthopoulos¹, F. Farowski¹, O. Krut², J. Ertel¹, H. Seifert¹, P. G. Higgins¹, ¹Cologne, ²Langen

P 19

Rapid identification of carbapenem-resistant *Acinetobacter baumannii* with a novel immunochromatographic lateral flow assay
 S. Mertins¹, P. G. Higgins¹, Q. Gillemann², P. Mertins², H. Seifert¹, M. Krönke¹, A. Klimka¹, ¹Cologne, ²Gembloux (Belgium)

P 20

CLAR – an automated cluster alert system to prevent the spread of multidrug-resistant organisms (NoSPREAD TTU 08.811 and 08.819)
 A. Rohde¹, C. Schröder¹, L.-A. Peña-Díaz¹, G. Pilarski¹, N. Thoma¹, B. Piening¹, H. Seifert²,
 M. Behnke¹, P. Gastmeier¹, ¹Berlin, ²Cologne

P 21

The dissemination of OXA-48 is driven by efficient horizontal gene transfer associated with a low fitness cost and low virulence
 A. Hamprecht¹, J. Sommer², C. Brender², M. Willmann³, F. Krause^{1,2}, Y. Stelzer¹, T. Tsvetkov¹,
 S. Riedel-Christ², J. Kutschenreuter², C. Imirzalioglu⁴, A. Gonzaga⁵, C. Spröer⁵, U. Nübel⁶, S. Göttig²,
¹Cologne, ²Frankfurt, ³Tuebingen, ⁴Gießen, ⁵Braunschweig

P 22

***Helicobacter pylori* infection alters the gastrointestinal microbiota of mice over time**
 N. Cullin, A. Raiser, R. Mejias-Luque, M. Gerhard, Munich

P 23

Erythrocyte remodeling in Plasmodium falciparum parasites during the dry season
 H. Fleckenstein¹, M. Cyrklaff¹, S. Doumbo², H. Cisse², D. Doumtabe², L. Djibo², S. Sacko²,
 T. Dombia², K. Kayentao², A. Ongoiba², O. Doumbo², B. Traore², P. Crompton³, S. Portugal¹
¹Heidelberg, ²Bamako (Mali), ³Maryland (USA)

P 24

Cost-efficient Hepatitis E Genomesequencing and Quasispecies Determination by Capture-Probe Targeting and Next Generation Sequencing (NGS)
 S. Gundlach^{1,2}, A. Leß^{1,2}, J. Huang¹, D. Indenbirken¹, C. Dahlke^{1,2}, S. Pischke^{1,2}, M. Lütgehetmann^{1,2},
 M. M. Addo^{1,2}, N. Fischer^{1,2}, ¹Hamburg, ²Hamburg-Lübeck-Borstel-Riems

SY II: NOVEL ANTI-INFECTIVES

P 25

SARS Unique Domain Regulates the Protein Level of Novel Antiviral Factor HDAC1 and Suppresses NF- κ B Signaling mediated by MKRN2 and HDAC1
 Y. Ma-Lauer, A. von Brunn, Munich

P 26

BTZ-043, an antituberculosis drug candidate: Results of the first in human clinical study and outlook to further development
 J. Dreisbach^{1,2}, F. Kloß², N. Heinrich¹, S. Konsten¹, F. Meyer², M. Hoelscher¹, ¹Munich, ²Jena

P 27

Novel vancomycin derivatives overcoming vancomycin-resistance show enhanced pharmacokinetics resulting in reduced renal accumulation
 F. Umstätter¹, C. Domhan¹, P. Uhl¹, B. Beijer¹, C. Kleist¹, K. Leotta¹, S. Zimmermann¹, M. Wink¹,
 K. D. Klika¹, U. Haberkorn¹, T. Hertlein², K. Ohlsen², W. Mier¹, ¹Heidelberg, ²Würzburg

P 28

Activation of silent secondary metabolite clusters by various regulatory proteins in Actinomycetes
 E. Mingyar, W. Wohlleben, E. Stegmann, Tübingen

P 29

Preclinical development of Corallopyronin A using physiology-based pharmacokinetic modeling and in vivo predictive biopharmaceutical in vitro tools
 A. K. Krome, A. Schiefer, S. Kehraus, S. Bouhired, M. P. Hübner, K. Pfarr, G. M. König, A. Hoerauf,
 K. G. Wagner, Bonn

P 30

Off-target-free AAV-mediated delivery of HIV-1 LTR-specific Recombinase
 N. Beschorner¹, J. Breuer², I. Hauber¹, F. Buchholz², J. Hauber¹, H. Büning²
¹Hamburg, ²Hanover, ³Dresden

P 31

A semi-automated, microscopy-based screening tool for the discovery of novel cell division inhibitors
 C. Matos de Opitz, H. Brötz-Oesterhelt, P. Sass, Tuebingen

P 32

A rapid point-of-care device for the diagnosis of Hepatitis Delta Virus infection
 F. A. Lempp¹, V. Sakin¹, S. Nkongolo¹, H. Wedemeyer^{2,3}, P. Schnitzler¹, S. Urban¹, ¹Heidelberg,
²Essen, ³Hanover

P 33**Identification of small chemical compounds blocking tegumentation and assembly of Herpes Simplex Virus**

J. C. Villalvazo Guerrero, A. Buch, D. Otoo, A. Pohlmann, G. Beauclair, J. Rückert, T. Schulz, B. Sodeik, Hanover

P 34**Vpu controls HIV-1 latency through modulation of the NF- κ B pathway**

G. Martrus¹, R. Cornelis¹, J. Brandi¹, S. Srinivasachar Badarinarayan², G. Haslé¹, A. Niehrs¹, J. Chow³, L. Hess¹, J. Bialek¹, A. Hoelzemer¹, W. Garcia-Beltrán^{1,4}, F. Kirchhoff², D. Sauter², M. Altfeld¹, ¹Hamburg, ²Ulm, ³Watertown (USA), ⁴Cambridge (USA)

P 35**A new antiviral approach – Inhibition of RNA viruses depending on eIF4A-dependent translation by the natural compound Silvestrol and synthetic analogues**

C. Müller¹, F. W. Schulte², K. Lange-Grünweller², S. Pleschka¹, J. Ziebuhr¹, R. Hartmann², A. Grünweller², ¹Giessen, ²Marburg

P 36**Identification of antibiotics that do not cause Shiga-toxin mediated renal disease in mice infected with *C. rodentium* Φ stx2dact**

S. Mühlen¹, M. Koeppel², B. Stecher², P. Dersch¹, ¹Braunschweig, ²Munich

P 37**Corallopyronin A: pre-clinical development through to phase I trial**

A. Schiefer¹, M. Stadler², K. Wagner³, R. Jansen², A. Krome³, S. Kehraus⁴, S. Hütte², M. Hübner¹, S. Bouhired⁴, D. Pogorevc³, T. Schäberle⁴, G. M. König⁴, R. Müller³, T. Hesterkamp², K. Pfarr¹, A. Hoerauf¹, ¹Bonn, ²Braunschweig, ³Saarbrücken, ⁴Gießen

P 38**A novel highly sensitive host cell-based high throughput drug screen targeting multi-drug resistant Gram-negative pathogens**

F. Schreiber, J. von Ambüren, J. Gräß, A. Schüller, S. Winter, E. van Gumpel, J. Rybniker, Cologne

P 39**Gb3-functionalized neoglycoproteins strongly inhibit Stx2d-mediated cytotoxicity towards kidney epithelial cells**

G. Pohlentz¹, J. Müthing¹, P. Dersch², H. Karch¹, ¹Münster, ²Braunschweig

P 40**Digging Through the Data: Computational Tools to Find Novel Antiinfectives**

M. Adamek, M. Alanjary, N. Ziemert, Tuebingen

P 41**iPSC-derived macrophages as a treatment approach for multidrug-resistant *Pseudomonas aeruginosa* infections in cystic fibrosis patients**

T. Wüstefeld, M.-L. Nawrot, T. Buchegger, N. Cramer, M. Ackermann, A. Munder, N. Lachmann, Hanover

P 42**Identification of novel antivirals targeting the human cytomegalovirus alkaline nuclease**

T. Potgieter¹, J. Rückert², A. Caceres-Nuñez¹, T. Schulz², E. Ostermann¹, W. Brune¹, ¹Hamburg, ²Hanover

P 43**Enabling the oral administration of myrcludex B by liposomal formulation**

P. Uhl, F. Helm, S. Urban, U. Haberkorn, G. Fricker, W. Mier, Heidelberg

P 44**Mechanism of action elucidation of two natural products combining lipid II binding with additional activities**

J. Deisinger¹, K. Ludwig¹, S. Tan², A. Mueller¹, F. J. Ortiz-López³, O. Genilloud³, J. Nodwell², T. Schneider¹, ¹Bonn, ²Toronto (Canada), ³Armillá (Spain)

P 45**Myxo versus Myco – and the winner is...**

J. Herrmann¹, A. Esser², E. van Gumpel², S. Hüttele³, R. Müller¹, N. Reiling⁴, J. Rybniker², ¹Saarbrücken, ²Cologne, ³Braunschweig, ⁴Borstel

P 46**Sensitizing *Staphylococcus aureus* to cationic anti-microbial peptides**

A. Jorge¹, U. Bilitewski^{2,3}, R. Müller^{2,3,4}, A. Peschel¹, ¹Tuebingen, ²Braunschweig, ³Hanover, ⁴Saarbrücken

P 47**Preclinical development of HY-133, a recombinant phage lysin for rapid decolonization of *Staphylococcus aureus* from nasal habitats**

E. Idelevich¹, S. Eisele², B. Krismer³, C. Weidenmaier³, A. Zipperer³, G. Winter², T. Hesterkamp⁴, W. Mutter⁵, K. Becker¹, A. Peschel³, ¹Münster, ²Munich, ³Tuebingen, ⁴Braunschweig, ⁵Bernried

P 48**Lugdunin and beyond: Modulating human microbiomes to exclude endogenous facultative pathogens**

B. Krismer, R. Rosenstein, A. Zipperer, C. Weidenmaier, A. Peschel, Tuebingen

P 49**Promising hit rate in a high throughput screening campaign of 50k small molecules targeting *Mycobacterium tuberculosis***

A. Esser¹, E. van Gumpel¹, J. Gräß¹, S. Winter¹, M. Neuenschwander², A. Oder², J. Rybniker¹, ¹Cologne, ²Berlin

P 50**DZIF TTU9 pharmacokinetic/pharmacodynamic (PK/PD) unit: Advancing compounds from bench to bedside**

K. Rox^{1,2}, E. Medina¹, T. Hesterkamp^{1,2}, R. Müller^{2,3}, M. Brönstrup^{1,2}, ¹Braunschweig, ²Hanover, ³Saarbrücken

P 51

Fragment-based carbapenemase inhibitors

R. Mejd-Nitiu¹, C. Softley¹, K. Zak¹, L. Goncalves¹, G. Popowicz¹, C. Grandclaudon², M. Brönstrup², U. Biletewski², R. Müller³, H. Meyer¹, ¹Munich, ²Braunschweig, ³Saarbrücken

P 52

Optimization of a novel TALEN targeting CCR5

L. I. Schwarze, U. Abramowski-Mock, B. Fehse, Hamburg

P 53

Genome sequencing of Corallopyronin A producing *Coralloccoccus coralloides* strains

S. Bouhired¹, O. Rupp², J. Blom², T. F. Schäberle², A. Schiefer¹, S. Kehraus¹, M. Roth³, K. Pfarr¹, A. Goemann², A. Hoerauf¹, G. M. König¹, ¹Bonn, ²Giessen, ³Jena

P 54

Mechanism of Action studies using a systematic analysis platform

I. Engels, A. Mueller, M. Rausch, A. Kloeckner, T. Schneider, Bonn

P 55

Targeting Latent Persistence of KSHV through Inhibition of LANA-DNA Interactions

M. Empting¹, P. Kirsch¹, V. Jakob¹, S. Stein², T. Schulz², ¹Saarbrücken, ²Hanover

P 56

Inhibitors of clinically relevant human polyomavirus infections

E. Kraus¹, J. Rückert^{2,3}, T. Schulz^{2,3}, A. Grundhoff¹, N. Fischer¹, ¹Hamburg, ²Hanover, ³Braunschweig

P 57

Matched pair analysis of patients treated for invasive mucormycosis – standard treatment vs. posaconazole novel formulations (MoveOn)

J. Salmanton-García, D. Seidel, L. Durán-Graeff, P. Köhler, S. Mellinshof, H. Wisplinghoff, J. J. Vehreschild, O. A. Cornely, M. J. G. T. Vehreschild, Cologne

P 58

Development of a novel drugs – An overview

S. Goy, T. Hestekamp, Braunschweig

P 59

Establishing High-throughput screening assays to identify novel antivirulence drugs targeting capsule biosynthesis in *Staphylococcus aureus*

M. Rausch, J. Deisinger, H. Ulm, A. Mueller, T. Schneider, F. Grein, Bonn

P 60

Development of small molecule inhibitors targeting the LMP1–TRAF2 protein-protein interaction

F. Giehler¹, S. Blazy^{1,2}, P. Kirsch^{2,4}, M. Ostertag¹, Y. Chen⁴, K. Schorpp¹, S. Dornauer¹, K. Hadian¹, G. Popowicz¹, M. Empting³, O. Plettenburg^{1,2}, J. Kirchmair⁴, A. Kieser¹, ¹Munich, ²Hanover, ³Saarbrücken, ⁴Hamburg

P 61

Development of a high-throughput in vitro assay for penicillin binding proteins from *Staphylococcus aureus*

N. Jelden, J.-S. Puls, I. Engels, M. Rausch, A. Mueller, T. Schneider, F. Grein, Bonn

P 62

Identification and characterization of novel respiratory chain inhibitors targeting *Helicobacter pylori*

C. Lettl¹, F. Schindele¹, T. Steiner¹, U. Biletewski², M. Witschel³, W. Eisenreich¹, W. Fischer¹, R. Haas¹, ¹Munich, ²Braunschweig, ³Ludwigshafen

P 63

Sensitizing *Staphylococcus aureus* to cationic antimicrobial peptides by MprF-inhibiting monoclonal antibodies

C. Slavetinsky, C. Ernst, A. Kraus, J. Hauser, A. Peschel, Tuebingen

P 64

Kynurenine is a cerebrospinal fluid biomarker for bacterial and viral CNS infections in humans

N. Novoselova¹, K.-W. Sühs², M. Kuhn³, V. Kaefer², F. Klawonn³, M. Stangel², F. Pessler³, ¹Minsk (Russia), ²Hanover, ³Braunschweig

P 65

Biological evaluation of novel small-molecule antiviral agents versus Tick Borne Encephalitis Virus

J. J. Bugert, Munich

P 66

***Salmonella* Typhimurium targets leptin signaling to modulate immune responses in macrophages**

J. Fischer, S. Gutiérrez, R. Ganesan, C. Calabrese, S. Khorasani, M. Wolke, P. Hartmann, J. C. Brüning, G. Plum, N. Robinson, Cologne

SY III: IMMUNOTHERAPY / VACCINES

P 67

A mosquito-transmittable blood stage attenuated malaria parasite for experimental vaccination

J. Sattler¹, C. Moreau¹, H. Prinz¹, J. Kehrer¹, M. Singer¹, D. Klug¹, S. Khan², C. Janse², F. Frischknecht¹, ¹Heidelberg, ²Leiden (Netherlands)

P 68

The Role of Clonal Selection versus Affinity Maturation in the Human B Cell Response to a Repetitive Malaria Parasite Antigen

H. Wardemann¹, T. TÜCHMI-002 study team^{2,3}, ¹Heidelberg, ²Tuebingen, ³Rockville (USA)

P 69**A virological response to PEG-IFN α treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study**

A. Wranke¹, C. Yurdaydin², B. Heidrich¹, K. Zachou³, K. Yalcin⁴, F. Tabak⁵, F. Lammert⁶, D. Häussinger⁷, T. Müller⁸, M. Wöbse¹, M. P. Manns¹, Wedemeyer^{1,9}, S. Hardtke¹, ¹Hanover, ²Ankara (Turkey), ³Larissa (Greece), ⁴Diyarbakir (Turkey), ⁵Istanbul (Turkey), ⁶Homburg, ⁷Duesseldorf, ⁸Berlin, ⁹Essen

P 70**Anopheles gambiae-transmitted controlled human malaria infections (by-bite CHMI) as a unique and versatile clinical trial platform**

S. Borrmann¹, A. A. Adegnika^{1,2}, A. McHardy³, R. Geffers³, J. Schmidt-Chanasit^{4,5}, ¹Tuebingen, ²Lambaréné (Gabon), ³Braunschweig, ⁴Hamburg, ⁵Hamburg-Luebeck-Borstel-Riems

P 71**MALACHITE: Safety and protective efficacy of intravenous immunization with cryopreserved Plasmodium falciparum sporozoites under atovaquone/proguanil chemoprophylaxis**

Z. Sulyok¹, M. Sulyok¹, H.-L. Heimann¹, F. O'Rourke¹, A. Lalremruata¹, T. Lucas Sandri¹, T. T. Nguyen¹, C. Lamsfus Calle¹, J. Ibanez Molina¹, P. Granados Bayon¹, R. Steuder¹, Z. Molnár¹, D. M. Weller¹, W. Metzger¹, J. Held¹, T. Gebru¹, A. Knoblich¹, B. K. L. Sim², T. L. Richie², S. L. Hoffman², B. Mordmüller^{1,3}, P. G. Kremsner^{1,3}, ¹Tuebingen, ²Rockville (USA), ³Lambaréné (Gabon)

P 72**Optimization of immunosuppressive treatment by pharmacodynamic monitoring in a multicenter approach**

C. Sommerer¹, O. Millan², O. Rissling³, K. Budde³, M. Brunet², L. Guirado², S. Meuer¹, M. Zeier¹, T. Giese¹, ¹Heidelberg, ²Barcelona (Spain), ³Berlin

P 73**Specific pharmacodynamics monitoring to detect patients on increased risk of viral complications**

C. Sommerer, P. Schnitzler, S. Meuer, M. Zeier, T. Giese, Heidelberg

P 74**The European Vaccine Initiative "Developing vaccines for diseases of poverty and emerging infectious diseases"**

H. Depraetere, N. Viebig, S. Jungbluth, O. Leroy, Heidelberg

P 75**Structure modelling and molecular dynamic simulation reveal conformational evolution of B-cell epitopes in norovirus GII.4 capsid protein**

S. Donakonda, H. Moeini, S. Qadir Afridi, P. Knolle, U. Protzer, D. Hoffmann, Munich

P 76**Orthotopic T cell receptor α and β chain replacement enables physiological T cell engineering**

K. Schober¹, T. Müller¹, F. Gökmen¹, S. Grassmann¹, K. Schumann¹, T. Roth², A. Marson², D. Busch¹, ¹Munich, ²San Francisco (USA)

P 77**Measuring Antiviral Capacity of T-cell Responses to Adenovirus**

A. Keib¹, Y.-F. Mei², L. Cicin-Sain³, D. H. Busch⁴, K. Dennehy¹, ¹Tuebingen, ²Umea (Sweden), ³Braunschweig, ⁴Munich

P 78**Treasure hunt: Ultrasensitive IP-10 quantification in the peripheral blood and GALT of long-term treated HIV infected individuals**

M. Augustin¹, C. Horn¹, M. S. Ercanoglu¹, V. Bondet², S.-H. Chon¹, C. Vivaldi¹, D. Nierhoff¹, I. Suarez¹, E. Knops¹, E. Heger¹, M. Oette¹, J. Rybniker¹, G. Fätkenheuer¹, F. Klein¹, M. Müller-Trutwin², D. Duffy², C. Lehmann¹, ¹Cologne, ²Paris (France)

P 79**Visualising Virus-T cell Interactions in lymphoid Tissues using combined in situ Hybridisation and fluorescence Immunohistochemistry**

K. Held¹, J. Anderson¹, H. Gruell², F. Klein², C. Lehmann², C. Geldmacher¹, ¹Munich, ²Cologne

P 80**Recombinant Modified Vaccinia virus Ankara delivering G and F antigens of Nipah Virus**

A. Volz¹, S. Veit¹, S. Jany¹, E. Dietzel², A. Kupke², S. Becker², G. Sutter¹, ¹Munich, ²Marburg

P 81**Comprehensive review of human P. falciparum malaria CD8+T cell epitopes**

J. Heide¹, K. Vaughan², T. Jacobs¹, J. Schulze zur Wiesch¹, ¹Hamburg, ²California (USA)

P 82**Epstein-Barr-Virus (EBV) genome analyses by next-generation sequencing directly from clinical specimens sampled from children with infectious mononucleosis (IMMUC study)**

A. Dhingra^{1,2}, C. Vogt^{1,2}, Z.-L. Deng², K. Gerrer³, R. Williams⁴, L. Steinbrueck¹, J. Geisberger³, L. Schulte-Hillen³, M. Bodenhausen³, F. Fischer³, P. Wallraven³, L. Werny³, T. Bauer³, N. Körber³, C. Richter³, J. Breuer⁴, A. McHardy², T. F. Schulz^{1,2}, U. Behrends³, T. Ganzmueller^{1,2}, ¹Hanover, ²Braunschweig, ³Munich, ⁴London (UK)

P 83**Characterization of CD8 T cell responses recognizing the MERS coronavirus nucleocapsid protein using MVA vector immunization in mice**

S. Veit, S. Jany, F. Song, R. Fux, G. Sutter, A. Volz, Munich

P 84**Identification of novel polysaccharide targets from Enterococcus faecium**

D. Laverde¹, L. F. Romero Saavedra¹, Z. Kaczynski², O. Holst³, J. Hübner¹, ¹Munich, ²Gdansk (Poland), ³Borstel

P 85**Broadening the coverage of a potential enterococcal vaccine by using immunogenic proteins as polysaccharide vaccine carriers**

L. F. Romero-Saavedra, D. Laverde, E. Kalfopoulou, J. Hübner, Munich

P 86

Multinational clinical trials: how do we collaborate?*S. A. Todagbe^{1,2}, B. Mordmüller^{1,2}, P. G. Kreamsner^{1,2}, ¹Lambaréné (Gabon), ²Tuebingen*

P 87

MCMV establishes persistent infection in kidneys upon congenital infection*M. Z. Chaudhry¹, A. Melk², L. Cicin-Sain¹, ¹Braunschweig, ²Hanover*

P 88

Impaired responsiveness to seasonal influenza vaccination in renal transplant recipients under active immunosuppression*J. Eggern¹, C. Sommerer¹, G. A. Kirchenbaum², M. Eggers³, P. Schnitzler¹, M. Zeier¹, P. V. Lehmann², T. Giese¹, ¹Heidelberg, ²Shaker Heights (USA), ³Stuttgart*

P 89

Immunophenotyping of stable renal transplant patients under active immunosuppression*J. Eggern, C. Sommerer, M. Zeier, T. Giese, Heidelberg*

P 90

Lower activation potential of neonatal monocytes as a factor for higher susceptibility to sepsis*C. Schlegel, B. Spring, N. Köstlin, C. Poets, C. Gille, Tuebingen*

P 91

Kinetics of Biomarkers during Ebola Virus Disease*R. Kerber¹, R. Krumkamp¹, M. Korva², T. Rieger¹, S. Wurr¹, S. Duraffour¹, L. Oestereich¹, M. Gabriel¹, D. Sissoko³, X. Anglaret^{3,4}, D. Malvy³, J. May¹, T. Avšič Županc², C. Muñoz-Fontela¹, S. Günther¹, ¹Hamburg, ²Ljubljana (Slovenia), ³Bordeaux (France), ⁴Abidjan (Côte d'Ivoire)*

P 92

Clinical development of a therapeutic antibody (StaphAcute) against antibiotic resistant Staphylococcus aureus*A. Klimka¹, S. Mertins¹, B. Tosetti¹, O. Krut², M. Krönke¹, ¹Cologne, ²Langen*

P 93

Big-data multidimensional bioinformatics analyses discriminates immunologic signatures of HCMV latent infections and reactivations in humanized mice*S. Theobald¹, H. Olbrich¹, S. Khailaie², M. Meyer-Hermann², M. Messerle¹, R. Stripecke¹, ¹Hanover, ²Braunschweig*

P 94

Spatio-temporally skewed activation of CD8+ PD-1+ T cells after EBV infection correlates with tumor development in long-term humanized mice*S. Danisch¹, C. Slabik¹, R. Zeidler², W. Hammerschmidt², F. Feuerhake¹, R. Stripecke¹, ¹Hanover, ²Munich*

P 95

Vaccination rates and responses of patients with liver cirrhosis: Results of a mono-centric prospective observational study*H. Sekhri, M. Wehmeyer, R. Wroblewski, T. Meyer, J. Schulze zur Wiesch, Hamburg*

P 96

Impact of Characteristics of Neutropenia on Infections – Comparing Factors Characterizing the Duration and Severity of Neutropenia*C. Jakob, A. Löhnert, M. Stecher, A. Hamprecht, N. Jazmati, O. Cornely, J. J. Vehreschild, Cologne*

P 97

Update on the Munich Infectious Mononucleosis (IMMUC) Study*M. Bodenhausen¹, K. Gerrer¹, L. Schulte-Hillen¹, J. Geisberger¹, A. Balteanu¹, N. Körber¹, C. Richter¹, P. Wallraven¹, L. Werny¹, F. Fischer¹, T. Bauer¹, D. Hoffmann¹, P. Luppa², R. Weggel¹, C. Meindl¹, J. Mautner¹, A. Moosmann², E. Nöbner¹, S. Fink³, H.-J. Delecluse³, T. Ganzenmüller², T. Schulz², M. Steinborn¹, S. Egert¹, F. Hauck¹, U. Behrends¹, ¹Munich, ²Hanover, ³Heidelberg*

P 98

Integrin a4b7 expression pattern of T cell subsets in HIV infected individuals and patients with inflammatory bowel disease*M. Wittner, J.-H. Bockmann, O. Seiz, C. Manthey, V. Schlicker, S. Huber, O. Degen, J. M. Eberhard, J. Schulze zur Wiesch, Hamburg*

P 99

Immunreconstitution of the T cell memory compartment and priming of de novo HIV-specific CD8 T cell responses in HIV-1 infected individuals after HSCT*J. M. Eberhard¹, M. Angin², M. Salgado³, B. Jensen⁴, E. Knops⁵, M. Christopheit¹, N. Kröger⁶, L. Vandekerckhove⁹, J. Badiola⁷, A. Bandera⁸, K. Raj⁹, J. van Lunzen^{1,9}, M. Kwon¹⁰, J. L. Diez Martin¹⁰, G. Hütter¹¹, V. Rocha¹², M. Nijhuis¹³, A. Wensing¹³, J. Martinez-Picado³, J. Schulze zur Wiesch¹, A. Sáez-Cirión², on behalf of the IciStem study group, ¹Hamburg, ²Paris (France), ³Barcelona (Spain), ⁴Duesseldorf, ⁵Cologne, ⁶Ghent (Belgium), ⁷Granada (Spain), ⁸Monza (Italy), ⁹London (UK), ¹⁰Madrid (Spain), ¹¹Dresden, ¹²Oxford (UK), ¹³Utrecht (Netherlands)*

P 100

IFN response suppresses HDV persistence during hepatocytes proliferation in vitro*Z. Zhang, Y. Ni, S. Urban, Heidelberg***SY IV: INFECTIONS OF THE LUNG**

P 101

Genetic screening of a cohort of 284 patients with the clinical diagnosis of hyper IgE syndrome and/or mucocutaneous candidiasis*H. Haberstroh, J. Rojas, K. Hübscher, M. Buchta, M. Proietti, N. Frede, A. Bulashevskaya, B. Grimbacher, Freiburg*

P 102

Detection and mapping of lipids and anti-TB drugs in mouse lung tissue via MALDI Mass Spectrometry*J. Kokesch-Himmelreich¹, A. Treu¹, K. Walter², J. Dreisbach³, N. Heinrich³, C. Hölscher², A. Römpf¹, ¹Bayreuth, ²Borstel, ³Munich*

P 103

***Pseudomonas aeruginosa* microevolution in cystic fibrosis lungs**
J. Klockgether, N. Cramer, S. Fischer, B. Tümmler, Hanover

P 104

Airways microbial metagenomes of individuals with immune deficiency, asthma, cystic fibrosis or COPD
L. Wiehlmann, K. Pienkowska, M. Gessner, M. Dorda, S. Hedtfeld, T. Scheithauer, J. Klockgether, C. Davenport, B. Tümmler, Hanover

P 105

Transplantation of Hematopoietic Stem Cells Improved Outcome of *P. aeruginosa* Lung Infection in a Cystic Fibrosis Mouse Model
A. Munder, K. Brinkert, C. Meinshausen, T. Buchegger, E. Lopez-Rodriguez, M. Ackermann, B. Tümmler, Hanover

P 106

Prospects for chemical p38 MAPK inhibition as host directed therapy against *Mycobacterium tuberculosis*
J. Gräßl, E. van Gumpel, C. Hölscher^{1,2}, M. Fritsch, C. Pallasch, H. Kashkar, J. Rybniker, ¹Cologne, ²Borstel

P 107

E-Health technology for infectious disease monitoring with a special focus on respiratory infections: Design Conception
J.-K. Heise, G. Krause, S. Castell, Braunschweig

P 108

Neutrophil associated signatures for point-of-care testing and putative targets for host-directed-therapy in tuberculosis
C. Leschczyk, T. Dallenga, B. Kalsdorf, A. Wutkowski, L. Kollipara, TB-Sequel Consortium, C. Lange, D. Schwudke, A. Sickmann, U. E. Schaible, ¹Borstel, ²Dortmund

P 109

Detection of heteroresistance in *Mycobacterium tuberculosis* complex populations using next-generation sequencing
V. Schleusener, S. Feuerriegel, S. Niemann, Borstel

P 110

The mycobacterial LytR-cpsA-Psr protein Rv3484 is essential to establish infection in the mouse model of tuberculosis and has an implication in susceptibility to meropenem/clavulanate and lysozyme
S. Malm, S. Maaß, U. E. Schaible, S. Ehlers, S. Niemann, Borstel

P 111

Evaluation of Next Generation Sequencing library preparation kits based on enzymatic fragmentation for medium and high throughput whole genome analysis of clinical *M. tuberculosis* complex strains
V. Mohr, Borstel

P 112

MTBseq: A comprehensive pipeline for whole genome sequence analysis of *Mycobacterium tuberculosis* complex isolates
T. Kohl, C. Utpatel, V. Schleusener, M. R. De Filippo, P. Beckert, D. M. Cirillo, S. Niemann, ¹Borstel, ²Milan (Italy)

P 113

Mycobacterial Phospholipids as Diagnostic Markers in Translational Research of Tuberculosis
F. Waldow, M. Weinkauff, V. Scholz, H. Karaköse, K. Walter, C. Hölscher, J. Brandenburg, N. Reiling, C. Lange^{1,2,3}, J. Heyckendorf, D. Schwudke, ¹Borstel, ²Lübeck, ³Stockholm (Sweden)

P 114

UPDATE - ten-year molecular epidemiological study of tuberculosis in Hannover, Germany
P. Beckert, M. Yilmaz, A. Hanke-Lensing, M. Bliemeister, C. Utpatel, T. A. Kohl, S. Gerdes^{1,2}, S. Niemann, ¹Borstel, ²Hanover

P 115

Inhibition of coronavirus replication in differentiated primary human bronchial epithelial cells using cyclophilin inhibitors
D. R. Bairad, Y. Ma-Lauer, B. von Brunn, M.-G. Stoleriu, A. Schamberger, C. Staab-Weijnitz, A. von Brunn, Munich

P 116

An improved mouse model for the preclinical evaluation of novel anti tuberculosis drug candidates -BTZ043-
K. Walter, J. Kokesch-Himmelreich, J. Dreisbach, N. Heinrich, A. Wieser, M. Hölscher, A. Römpf, C. Hölscher, ¹Borstel, ²Kulmbach, ³Munich

P 117

Harmonized genome wide typing of tubercle bacilli using a web-based Gene-by-Gene nomenclature system
T. Kohl, D. Harmsen, J. Rothgänger, T. Walker, R. Diehl, S. Niemann, ¹Borstel, ²Münster, ³Oxford (UK), ⁴Kiel

P 118

Therapeutic Drug Monitoring Platform for Patients with MDR-TB
P. Sanchez-Carballo, N. Köhler, H.-P. Grobbel, H. Karaköse, F. Waldow, C. Lange^{1,2,3}, D. Schwudke, ¹Borstel, ²Lübeck, ³Stockholm (Sweden)

P 119

Small noncoding RNAs in peripheral blood as biomarkers for tuberculosis
L. de Araujo, M. Ribeiro-Alves, S. Talbot, A. Tallam, T. Calvo, F. Mello, R. Geffers, M. H. Saad, F. Pessler, ¹Hanover, ²Rio de Janeiro (Brazil), ³Braunschweig

P 120

Aconitate decarboxylase and itaconic acid reduce inflammation and host susceptibility in influenza A virus infection
N. Sahini, A. A. Iqbal, T. Ebenson, A. Sohail, M. Pils, C. A. Guzman, C. Falk, V. Kaever, A. Michelucci, F. Pessler^{1,2}, ¹Hanover, ²Braunschweig, ³Luxembourg (Luxembourg)

SY V: GLOBAL INTERVENTION EFFECTIVENESS

P 121

Congruency of clinical diagnosis and administered drug according to national treatment guideline in paediatric patients with severe febrile illnesses in rural Burkina Faso

J. Kompenhans¹, C. Dah², M. Seynou², B. Coulibaly², A. Sié², S. Gies^{1,3}, R. Sauerborn¹, A. Souares¹, ¹Heidelberg, ²Nouna (Burkina Faso), ³Würzburg

P 122

TI 03.907 Development of novel diagnostic tests to support the elimination of the Neglected Tropical Diseases: onchocerciasis, geohelminths and schistosomiasis

A. Hörauf^{1,2}, K. Pfarr^{1,2}, A. Kreidenweiss³, N. Schwarz⁴, I. Kroid^{5,6}, S. Wanji¹, A. Y. Debrah^{2,6}, A. A. Adegniko³, R. Rakotozandrindrainy⁴, M. R. Andrianarivelo⁴, M. Chachage⁵, U. Klarmann-Schulz^{1,2}, M. Esen³, J. May⁴, E. Tannich⁴, M. Hoelscher^{5,6}, C. Koehler³, ¹DZIF Partnersite Bonn-Köln, with African partner Buea, Cameroon, ²DZIF Partnersite Bonn-Köln, with African partner Kumasi, Ghana, ³DZIF Partnersite Tuebingen, with African partner Lambaréné, Gabon, ⁴DZIF Partnersite Hamburg, with African partner Antananarivo, Madagascar, ⁵DZIF Partnersite Munich, with African partner Mbeya, Tanzania, ⁶DZIF Partnersite München, with African partner Kumasi, Ghana

P 123

Hepatitis D Epidemiology in Germany: Existing evidence and gaps

I. Sperle-Heupel, R. Zimmermann, G. Steffen, N. Sarma, S. Beermann, R. Thamm, V. Bremer, S. Dudareva, Berlin

P 124

Faecal bile acid concentrations predict response to faecal microbiota transplantation in patients with recurrent *C. difficile* infection

F. Farowski¹, P. Solbach², A. Tsakmaklis¹, S. Brodesser¹, M. R. Cruz Aguilar¹, O. A. Cornely¹, K. Dettmer¹, P. G. Higgins¹, S. Suerbaum^{2,4}, N. Jazmati¹, P. J. Oefner³, M. Vehreschild¹, ¹Cologne, ²Hanover, ³Regensburg, ⁴Munich

P 125

Searching for different pathogens in breeding colonies of wild-derived rats in Germany

E. Heuser¹, G. Wilharm², T. Eisenberg³, K. Schmidt⁴, R. Ryll¹, K. Wernike¹, B. Hoffmann¹, F.-R. Matuschka⁵, R. Ulrich¹, ¹Greifswald, ²Wernigerode, ³Giessen, ⁴Heidelberg, ⁵Potsdam

P 126

Know your epidemic – generating baseline evidence for monitoring viral hepatitis C elimination in Germany

R. Zimmermann, I. Sperle-Heupel, G. Steffen, N. Sarma, S. A. Leendertz, S. Beermann, T. Roma, V. Bremer, S. Dudareva, Berlin

P 127

Chronic viral hepatitis B: prevalence and risk factors in Nouna, Burkina Faso

M. Seynou¹, A. Ouédraogo¹, A. Sié¹, B. Coulibaly¹, P. Zabré¹, S. Gies², J. J. Ott³, G. Krause³, R. Sauerborn⁴, A. Souares⁴, ¹Nouna (Burkina Faso), ²Würzburg, ³Braunschweig, ⁴Heidelberg

P 128

Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015 — a retrospective observational study

R. Kerber¹, E. Lorenz¹, S. Duraffour¹, D. Sissoko², X. Anglaret^{2,3}, D. Malvy², S. Günther¹, ¹Hamburg, ²Bordeaux (France), ³Abidjan (Côte d'Ivoire)

P 129

Creating evidence basis to monitor progress of viral hepatitis elimination goals in Germany

S. Dudareva, I. Sperle, G. Steffen, N. Sarma, S. A. Leendertz, S. Beermann, R. Thamm, V. Bremer, R. Zimmermann, Berlin

P 130

Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak

L. E. Kafetzopoulou^{1,2}, S. T. Pullan¹, P. Lemey³, D. Ehichioya², M. Pahlmann², A. Thielebein², J. Hinzmann², L. Oestereich², Y. Ighodalo⁴, D. Adomeh⁴, T. Olokor², C. Ihekweazu⁵, P. Formenty⁶, S. Okogbenin⁴, E. Ogbaini-Emovon⁴, S. Günther², S. Duraffour², ¹Porton Down (UK), ²Hamburg, ³Leuven (Belgium), ⁴Irrua (Nigeria), ⁵Abuja (Nigeria), ⁶Geneva (Switzerland)

A

Adamek, M. p.18
 Addo, M. p.9
 Ahmed, M. p.9
 Augustin, M. p.23

B

Bachmann, O. p.7,14
 Bärnighausen, T. p.10
 Bairad, D. p.7, p.27
 Becker, S. p.8
 Beckert, P. p.27
 Behrends, U. p.10
 Beschorner, N. p.17
 Bodenhausen, M. p.25
 Borrmann, S. p.22
 Bouhired, S. p.20
 Brandenburg, J. p.9
 Bugert, J. p.21

C

Chaudhry, M. p.24
 Cicin-Sain, L. p.8
 Cornely, O. p.9
 Cullin, N. p.16

D

Dallenga, T. p.8
 Dalpke, A. p.9
 Danisch, S. p.24
 de Araujo, L. p.27
 Deisinger, J. p.19
 Dennehy, K. p.23
 Depraetere, H. p.22
 Dhingra, A. p.23
 Dietz, J. p.6
 Doijad, S. p.6
 Donakonda, S. p.22
 Dreisbach, J. p.17
 Dudareva, S. p.29
 Duraffour, S. p.29

E

Eberhard, J. p.25
 Eggern, J. p.24
 Eisenbeis, S. p.15
 Empting, M. p.20
 Engels, I. p.20
 Escudero Perez, B. p.6
 Esser, A. p.19

F

Falgenhauer, L. p.14
 Fathi, A. p.8
 Fischer, N. p.20
 Fischer, J. p.21
 Fleckenstein, H. p.16

G

Giehler, F. p.20
 Goncalves, L. p.20
 Goy, S. p.20
 Gräß, J. p.26
 Gundlach, S. p.16
 Gwozdzinski, K. p.15

H

Haberstroh, H. p.25
 Haid, S. p.9
 Hammerschmidt, W. p.8
 Hamprecht, A. p.16
 Hardtke, S. p.22
 Hegg, K. p.6
 Heide, J. p.23
 Heise, J. p.26
 Held, K. p.23
 Herold, S. p.9
 Heyckendorf, J. p.9
 Hölscher, M. p.10
 Hölzl, F. p.14
 Hörauf, A. p.28
 Holden, M. p.6

J

Jakob, C. p.25
 Jelden, N. p.21
 Jorge, A. p.19

K

Kaiser, R. p.7,11
 Kaysser, L. p.7
 Kerber, R. p.24,29
 Klimka, A. p.24
 Klockgether, J. p.26
 Kohl, T. p.27
 Kokesch-Himmelreich, J. p.25
 Kompenhans, J. p.28
 Krismer, B. p.19
 Krönke, M. p.6
 Krome, A. p.17

L

Laverde, D. p.23
 Leschczyk, C. p.26
 Lettl, C. p.21

M

Ma-Lauer, Y. p.17
 Malm, S. p.26
 Martrus, G. p.8
 Matos de Opitz, C. p.17
 May, J. p.10
 Meier, C. p.7
 Mellinghof, S. p.10
 Mertins, S. p.16
 Mier, W. p.7
 Mingyar, E. p.17
 Mohr, V. p.26
 Mordmüller, B. p.8
 Mühlen, S. p.18
 Müller, C. p.14
 Müller, C. p.18
 Munder, A. p.26

N

Nelson, E. p.15
 Nkongolo, S. p.7
 Nürnberger, C. p.8

P

Peschel, A. p.6,19
 Pessler, F. p.21
 Pohlentz, G. p.18
 Portugal, S. p.6,11
 Potgieter, T. p.9
 Protzer, U. p.10

R

Rausch, M. p.20
 Rohde, A. p.16
 Romero-Saavedra, L. p.23
 Rox, K. p.19
 Rybniker, J. p.19

S

Sahini, N. p.27
 Sakin, V. p.17
 Salmanton-García, J. p.20
 Sanchez-Carballo, P. p.27
 Sattler, J. p.31
 Schiefer, A. p.18
 Schlegel, C. p.24
 Schleusener, V. p.26
 Schneider, T. p.7
 Schober, K. p.22
 Schreiber, F. p.18
 Schwarze, L. p.20
 Schwinghammer, S. p.15
 Sekhri, H. p.24
 Seynou, M. p.28
 Sierra, S. p.15
 Slavetinsky, C. p.21
 Sommerer, C. p.22
 Sperle-Heupel, I. p.28
 Stecher, M. p.14
 Suljok, Z. p.22

T

Theobald, S. p.24
 Titz, A. p.7
 Todagbe, S. p.24
 Tsakmaklis, A. p.28
 Tu, T. p.14

U

Uhl, P. p.19
 Ulrich, R. p.28
 Umstätter, F. p.17
 Urban, S. p.9
 Utpatel, C. p.27

V

van Alen, S. p.6
 Vehreschild, J. p.7
 Vehreschild, M. p.11,15
 Villalvazo Guerrero, J. p.18
 Volz, A. p.23

W

Waldow, F. p.27
 Walter, K. p.27
 Wardemann, H. p.21
 Welte, T. p.9
 Willmann, M. p.15
 Wittner, M. p.25
 Wüstefeld, T. p.18
 Wunderlich, A. p.15

X

Xanthopoulou, K. p.16

Y

Yao, Y. p.16

Z

Zhang, Z. p.25
 Zimmermann, M. p.10
 Zimmermann, R. p.28

Venue

Kongresshaus Stadthalle Heidelberg
 Neckarstadt 24 · 69117 Heidelberg
www.heidelberg-kongresshaus.de

Scientific Organizer

German Center for Infection Research e.V. (DZIF)
 Inhoffenstr. 7 · 38124 Braunschweig
www.dzif.de

Congress Organization

COCS GmbH · Congress Organisation C. Schäfer
 Rosenheimer Str. 145 c · 81671 Munich
 Phone: +49 (0)89/890677-0
 Fax: +49 (0)89/890677-77
 Email: felicitas.molnar@cocs.de

**Opening Hours
Registration Desk**

Monday, 3 December 2018	09:00 – 18:00
Tuesday, 4 December 2018	08:00 – 17:00

**Poster viewing &
Get together
with food and drinks**

Monday, 3 December 2018, from 18:10

Take advantage of this opportunity to speak to and interact with experts in various spheres of infectious diseases and to ask questions you may have. Relax after a busy congress day and enjoy interesting conversations with colleagues and friends.

**A registration for participation is absolutely necessary.
There will be no extra charge.**

Certification

All participants will receive a confirmation of participation at the beginning of the conference with your registration at the congress office on site. The conference is certified by the State Medical Board of Registration for Baden-Württemberg with 12 CME points in category B. The conference is also certified with 20 iCME points by the Akademie für Infektionsmedizin e.V.



Registration	Please register for the conference until 15 November 2018 at www.dzif-annual-meeting2018.de .				
Participation fee	<table> <tr> <td>Participant</td> <td>EUR 120,-</td> </tr> <tr> <td>Doctoral student/student*</td> <td>free entry</td> </tr> </table> <p>*) Please fax verification to +49 (0)89/890677-77. Without verification, the full price will be charged.</p> <p>After you register, you will receive a confirmation and payment request. Please note that after 15 November 2018, payment can only be made at the venue.</p>	Participant	EUR 120,-	Doctoral student/student*	free entry
Participant	EUR 120,-				
Doctoral student/student*	free entry				
Payment	<p>Please note „DZIF2018“ and the participant's name as intended purpose of the transfer:</p> <p>COCS GmbH HypoVereinsbank Munich IBAN: DE30 7002 0270 0039 6131 40 BIC: HYVEDE MMXXX Reference: last name, first name & „DZIF2018“</p> <p>Please note that we do not cover any bank charges.</p>				
Cancellation	For written cancellation by 15 November 2018, a cancellation fee of 30,- EUR will be charged. After this closing date, no refund of the participation fee is possible.				
Contact	COCS GmbH · Congress Organisation C. Schäfer Felicitas Molnar Tel. +49 (0)89/890677-17 Email: felicitas.molnar@coocs.de				
Employer authorization	For the purposes of the FSA codex we kindly ask for participation clinicians/scientists as employed to obtain an authorization from your employer to participate in the conference if necessary. The congress is supported by pharmaceutical/medical companies. The sponsors have no influence on the scientific programme. The special sponsor symposium is clearly marked.				

Sponsors

We thank our sponsors very much for their support:

**Exhibitors**

Intavis Bioanalytical Instruments AG
EUR 1.500,- Sponsoring / Booth
www.intavis.com

Janssen-Cilag GmbH, Neuss
EUR 2.300,- Sponsoring / Booth
www.janssen.com/germany

MSD SHARP & DOHME GMBH, Haar
EUR 11.800,- Sponsoring / Symposium / Poster Awards / Booth
www.msd.de

Status printdate: Oktober 2018 - without engagement

Arrival by car

Motorways A5/A6, direct motorway on-ramps and exits from/to Heidelberg via the A5/A656 (Darmstadt-Karlsruhe-Basel).

On entering the city, there are already indications of possibilities for parking. At the end of the autobahn, in Speyererstraße and Schlierbacher Landstrasse, there are direction signs for three destination areas:

- Zentrum
- Altstadt / Schloss
- Stadthalle Kongresshaus

The best parking possibilities for visitors of the convention center are parking garages P6 and P8 in the convention center area.

- P8 "Kongresshaus", Untere Neckarstraße 44 , 69117 Heidelberg
- P6 "Kraus", Untere Neckarstraße 2, 69117 Heidelberg

Heidelberg has an environmental zone, into which only vehicles which meet certain emissions standards are permitted to drive. Cars which are used in the Green Zone must be equipped with a sticker that indicates their emissions group. Please note that from January 2013 even the yellow sticker will be no longer permitted, you need a green sticker to drive in the environmental zones.

Arrival by public transportation**From Central Station Heidelberg**

Take the bus 35 (direction Heidelberg, Universitätsplatz) and get off at station „Kongresshaus“. For further information please visit www.vrn.de.

From Airport Mannheim

Take train 5 to Heidelberg and exit at station „Heidelberg Main Station“. Take the bus 35 (direction Heidelberg, Universitätsplatz) and get off at station „Kongresshaus“.

Arrival by railway – with Deutsche Bahn

COCS GmbH - Congress Organisation C. Schäfer offers you exclusive discounted tickets in cooperation with the Deutsche Bahn for your travel to the DZIF meeting.

You can book your event ticket at a national fixed price from every Deutsche Bahn railway station (while stocks last).

Event ticket (one-way) for a specific train (while stocks last):

- 2nd Class EUR 49,50
- 1st Class EUR 79,50

Event ticket (one-way) totally flexible (always available):

- 2nd Class EUR 69,50
- 1st Class EUR 99,50

Book your ticket online at www.cocs.de or under the service number +49 (0)1806 - 31 11 53 with keyword „COCS“.

Location

◀ Heidelberg, Main Station/HBF

Heidelberg Schloss ▶

SAVE
THE
DATE

21.–23. November
2019

Hotel Dolce, Bad Nauheim

**Joint Annual Meeting/
Gemeinsame Jahrestagung**

German Society of Infectious Diseases (DGI)
German Center for Infection Research (DZIF)

**Scientific Coordination /
Wissenschaftliche Koordination**

Prof. Dr. Hortense Slevogt, Jena (DGI)
Prof. Dr. Jan Rupp, Lübeck (DGI)
Prof. Dr. Trinad Chakraborty, Giessen (DZIF)
Prof. Dr. Stephan Becker, Marburg (DZIF)

www.dgi-dzif-kongress2019.de

Imprint

Conference Director and responsible for editorial content:

Dr. Timo Jäger
German Center for Infection Research e.V. (DZIF)
Inhoffenstr. 7 · 38124 Braunschweig

Design & Layout

COCS media GmbH
Rosenheimer Str. 145c · 81671 Munich
www.cocs-media.de



COCS media GmbH does not guarantee the correctness of information.

